Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
62
LABS.TO Quote, Financials, Valuation and Earnings
Last price:
$0.08
Seasonality move
:
-4.2%
Day range:
$0.07 - $0.08
52-week range:
$0.06 - $0.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.68x
P/B ratio:
0.83x
Volume:
37.9K
Avg. volume:
382.6K
1-year change:
15.38%
Market cap:
$31.6M
Revenue:
$42M
EPS (TTM):
-$0.02
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LABS.TO
MediPharm Labs Corp.
|
$12.4M | -$0.01 | -1.82% | -- | -- |
|
ACB.TO
Aurora Cannabis, Inc.
|
$99M | -$0.03 | 4.79% | -91.67% | $7.80 |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HITI.V
High Tide, Inc.
|
$178.4M | -$0.01 | 25.2% | -97.56% | $7.75 |
|
ZEN.V
Zentek Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LABS.TO
MediPharm Labs Corp.
|
$0.08 | -- | $31.6M | -- | $0.00 | 0% | 0.68x |
|
ACB.TO
Aurora Cannabis, Inc.
|
$6.27 | $7.80 | $354.7M | 116.20x | $0.00 | 0% | 0.96x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HITI.V
High Tide, Inc.
|
$3.89 | $7.75 | $338.9M | -- | $0.00 | 0% | 0.57x |
|
ZEN.V
Zentek Ltd.
|
$1.00 | -- | $107.3M | -- | $0.00 | 0% | 114.11x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LABS.TO
MediPharm Labs Corp.
|
1.11% | -1.209 | 1.34% | 1.97x |
|
ACB.TO
Aurora Cannabis, Inc.
|
15.87% | 1.055 | 19.86% | 1.52x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HITI.V
High Tide, Inc.
|
36.24% | 2.359 | 32.33% | 1.22x |
|
ZEN.V
Zentek Ltd.
|
13.91% | -0.347 | 1.7% | 0.41x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LABS.TO
MediPharm Labs Corp.
|
$2.4M | -$2.1M | -18.99% | -19.19% | -18.68% | -$127K |
|
ACB.TO
Aurora Cannabis, Inc.
|
-$8M | -$56M | -9.13% | -10.69% | -61.96% | -$46.7M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HITI.V
High Tide, Inc.
|
$14.9M | $5.4M | -4.42% | -6.56% | 3.6% | $8.4M |
|
ZEN.V
Zentek Ltd.
|
-$1.2M | -$2.4M | -50.39% | -54.49% | -38887.1% | -$1.5M |
MediPharm Labs Corp. vs. Competitors
-
Which has Higher Returns LABS.TO or ACB.TO?
Aurora Cannabis, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of -58.83%. MediPharm Labs Corp.'s return on equity of -19.19% beat Aurora Cannabis, Inc.'s return on equity of -10.69%.
Company Gross Margin Earnings Per Share Invested Capital LABS.TOMediPharm Labs Corp.21.17% -$0.01 $38.3M ACB.TOAurora Cannabis, Inc.-8.86% -$0.91 $667.4M -
What do Analysts Say About LABS.TO or ACB.TO?
MediPharm Labs Corp. has a consensus price target of --, signalling upside risk potential of 33.33%. On the other hand Aurora Cannabis, Inc. has an analysts' consensus of $7.80 which suggests that it could grow by 24.4%. Given that MediPharm Labs Corp. has higher upside potential than Aurora Cannabis, Inc., analysts believe MediPharm Labs Corp. is more attractive than Aurora Cannabis, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABS.TOMediPharm Labs Corp.0 1 0 ACB.TOAurora Cannabis, Inc.2 2 0 -
Is LABS.TO or ACB.TO More Risky?
MediPharm Labs Corp. has a beta of 0.637, which suggesting that the stock is 36.251% less volatile than S&P 500. In comparison Aurora Cannabis, Inc. has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.781%.
-
Which is a Better Dividend Stock LABS.TO or ACB.TO?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurora Cannabis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Aurora Cannabis, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABS.TO or ACB.TO?
MediPharm Labs Corp. quarterly revenues are $11.4M, which are smaller than Aurora Cannabis, Inc. quarterly revenues of $90.4M. MediPharm Labs Corp.'s net income of -$2.1M is higher than Aurora Cannabis, Inc.'s net income of -$53.2M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Aurora Cannabis, Inc.'s PE ratio is 116.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.68x versus 0.96x for Aurora Cannabis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABS.TOMediPharm Labs Corp.0.68x -- $11.4M -$2.1M ACB.TOAurora Cannabis, Inc.0.96x 116.20x $90.4M -$53.2M
-
Which has Higher Returns LABS.TO or COOL.CX?
Core One Labs, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of --. MediPharm Labs Corp.'s return on equity of -19.19% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABS.TOMediPharm Labs Corp.21.17% -$0.01 $38.3M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About LABS.TO or COOL.CX?
MediPharm Labs Corp. has a consensus price target of --, signalling upside risk potential of 33.33%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that MediPharm Labs Corp. has higher upside potential than Core One Labs, Inc., analysts believe MediPharm Labs Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LABS.TOMediPharm Labs Corp.0 1 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is LABS.TO or COOL.CX More Risky?
MediPharm Labs Corp. has a beta of 0.637, which suggesting that the stock is 36.251% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock LABS.TO or COOL.CX?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABS.TO or COOL.CX?
MediPharm Labs Corp. quarterly revenues are $11.4M, which are larger than Core One Labs, Inc. quarterly revenues of --. MediPharm Labs Corp.'s net income of -$2.1M is higher than Core One Labs, Inc.'s net income of --. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.68x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABS.TOMediPharm Labs Corp.0.68x -- $11.4M -$2.1M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns LABS.TO or CURE.X.CX?
Biocure Technology has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of --. MediPharm Labs Corp.'s return on equity of -19.19% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LABS.TOMediPharm Labs Corp.21.17% -$0.01 $38.3M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About LABS.TO or CURE.X.CX?
MediPharm Labs Corp. has a consensus price target of --, signalling upside risk potential of 33.33%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that MediPharm Labs Corp. has higher upside potential than Biocure Technology, analysts believe MediPharm Labs Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings LABS.TOMediPharm Labs Corp.0 1 0 CURE.X.CXBiocure Technology0 0 0 -
Is LABS.TO or CURE.X.CX More Risky?
MediPharm Labs Corp. has a beta of 0.637, which suggesting that the stock is 36.251% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock LABS.TO or CURE.X.CX?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABS.TO or CURE.X.CX?
MediPharm Labs Corp. quarterly revenues are $11.4M, which are larger than Biocure Technology quarterly revenues of --. MediPharm Labs Corp.'s net income of -$2.1M is higher than Biocure Technology's net income of --. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.68x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABS.TOMediPharm Labs Corp.0.68x -- $11.4M -$2.1M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns LABS.TO or HITI.V?
High Tide, Inc. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of 0.56%. MediPharm Labs Corp.'s return on equity of -19.19% beat High Tide, Inc.'s return on equity of -6.56%.
Company Gross Margin Earnings Per Share Invested Capital LABS.TOMediPharm Labs Corp.21.17% -$0.01 $38.3M HITI.VHigh Tide, Inc.9.95% $0.01 $223.9M -
What do Analysts Say About LABS.TO or HITI.V?
MediPharm Labs Corp. has a consensus price target of --, signalling upside risk potential of 33.33%. On the other hand High Tide, Inc. has an analysts' consensus of $7.75 which suggests that it could grow by 99.23%. Given that High Tide, Inc. has higher upside potential than MediPharm Labs Corp., analysts believe High Tide, Inc. is more attractive than MediPharm Labs Corp..
Company Buy Ratings Hold Ratings Sell Ratings LABS.TOMediPharm Labs Corp.0 1 0 HITI.VHigh Tide, Inc.6 0 0 -
Is LABS.TO or HITI.V More Risky?
MediPharm Labs Corp. has a beta of 0.637, which suggesting that the stock is 36.251% less volatile than S&P 500. In comparison High Tide, Inc. has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.811%.
-
Which is a Better Dividend Stock LABS.TO or HITI.V?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. High Tide, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. High Tide, Inc. pays out 5.25% of its earnings as a dividend. High Tide, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios LABS.TO or HITI.V?
MediPharm Labs Corp. quarterly revenues are $11.4M, which are smaller than High Tide, Inc. quarterly revenues of $149.7M. MediPharm Labs Corp.'s net income of -$2.1M is lower than High Tide, Inc.'s net income of $832K. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while High Tide, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.68x versus 0.57x for High Tide, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABS.TOMediPharm Labs Corp.0.68x -- $11.4M -$2.1M HITI.VHigh Tide, Inc.0.57x -- $149.7M $832K
-
Which has Higher Returns LABS.TO or ZEN.V?
Zentek Ltd. has a net margin of -18.71% compared to MediPharm Labs Corp.'s net margin of -38567.74%. MediPharm Labs Corp.'s return on equity of -19.19% beat Zentek Ltd.'s return on equity of -54.49%.
Company Gross Margin Earnings Per Share Invested Capital LABS.TOMediPharm Labs Corp.21.17% -$0.01 $38.3M ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M -
What do Analysts Say About LABS.TO or ZEN.V?
MediPharm Labs Corp. has a consensus price target of --, signalling upside risk potential of 33.33%. On the other hand Zentek Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that MediPharm Labs Corp. has higher upside potential than Zentek Ltd., analysts believe MediPharm Labs Corp. is more attractive than Zentek Ltd..
Company Buy Ratings Hold Ratings Sell Ratings LABS.TOMediPharm Labs Corp.0 1 0 ZEN.VZentek Ltd.0 0 0 -
Is LABS.TO or ZEN.V More Risky?
MediPharm Labs Corp. has a beta of 0.637, which suggesting that the stock is 36.251% less volatile than S&P 500. In comparison Zentek Ltd. has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.176%.
-
Which is a Better Dividend Stock LABS.TO or ZEN.V?
MediPharm Labs Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zentek Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediPharm Labs Corp. pays -- of its earnings as a dividend. Zentek Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LABS.TO or ZEN.V?
MediPharm Labs Corp. quarterly revenues are $11.4M, which are larger than Zentek Ltd. quarterly revenues of $6.2K. MediPharm Labs Corp.'s net income of -$2.1M is higher than Zentek Ltd.'s net income of -$2.4M. Notably, MediPharm Labs Corp.'s price-to-earnings ratio is -- while Zentek Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediPharm Labs Corp. is 0.68x versus 114.11x for Zentek Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LABS.TOMediPharm Labs Corp.0.68x -- $11.4M -$2.1M ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
